Skip to main content
Fig. 3 | BMC Cancer

Fig. 3

From: The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors

Fig. 3

Comparison of irAEs and irSAEs between published RCTs of ICIs and corresponding registration at ClinicalTrials.gov. The order of the categories in each row from left to right: complete match, partial match, not a match, not comparable (due to results missing from CT.gov results, results missing in the published article, or results missing from both sources). The comparison of safety indicators specific to ICIs, immune-related AEs (irAEs) and serious immune-related AEs (irSAEs) between the two sources (published trials and corresponding registration) is determined using the approach depicted in Additional file 4: Figure S1

Back to article page
\